CO5241328A1 - Constructo de adn para la obtencion recombinante de saratina - Google Patents

Constructo de adn para la obtencion recombinante de saratina

Info

Publication number
CO5241328A1
CO5241328A1 CO00019687A CO00019687A CO5241328A1 CO 5241328 A1 CO5241328 A1 CO 5241328A1 CO 00019687 A CO00019687 A CO 00019687A CO 00019687 A CO00019687 A CO 00019687A CO 5241328 A1 CO5241328 A1 CO 5241328A1
Authority
CO
Colombia
Prior art keywords
collagen
natural
protein
cells
medicinalis
Prior art date
Application number
CO00019687A
Other languages
English (en)
Inventor
Wolfgang Strittmatter
Detlef Guessow
Uwe Hofmann
Juergen Hemberger
Zisi Fotev
Bernhard Scheuble
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CO5241328A1 publication Critical patent/CO5241328A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe una proteína natural aislada de la saliva de la sanguijuela medicinal Hirudo medicinalis que se une fuertemente al colágeno, actuando de esta manera como un inhibidor de la adherencia natural de las plaquetas al colágeno. La proteína tiene un peso molecular de aproximadamente 12000, un punto isoeléctrico ácido y contiene seis cisteínas. La proteína fue secuenciada y el gen fue clonado a partir de la biblioteca de ADNc de H. Medicinalis. También se dan a conocer procedimientos para producir tal polipéptido por medio de técnicas recombitantes. Tanto las proteínas naturales como las quiméricas son inhibidores potentes de la adherencia de plaquetas dependiente del colágeno y, por lo tanto, pueden ser utilizadas para el tratamiento terapéutico de diversas condiciones relacionadas con la enfermedad cardíaca y las enfermedades del sistema circulatorio. Además, la proteína también es apropiada para recubrir superficies naturales o artificiales de colágeno con el fin de volverlas no adhesivas para las células y de esta manera prevenir la activación de células.
CO00019687A 1999-03-18 2000-03-17 Constructo de adn para la obtencion recombinante de saratina CO5241328A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99105530 1999-03-18
EP99109503 1999-05-12

Publications (1)

Publication Number Publication Date
CO5241328A1 true CO5241328A1 (es) 2003-01-31

Family

ID=26152935

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00019687A CO5241328A1 (es) 1999-03-18 2000-03-17 Constructo de adn para la obtencion recombinante de saratina

Country Status (27)

Country Link
US (3) US6774107B1 (es)
EP (1) EP1161530B1 (es)
JP (1) JP4805461B2 (es)
KR (1) KR100788219B1 (es)
CN (1) CN1185344C (es)
AR (1) AR023099A1 (es)
AT (1) ATE295883T1 (es)
AU (1) AU767172B2 (es)
BR (1) BR0009074A (es)
CA (1) CA2367457C (es)
CO (1) CO5241328A1 (es)
CZ (1) CZ301524B6 (es)
DE (1) DE60020220T2 (es)
DK (1) DK1161530T3 (es)
ES (1) ES2240067T3 (es)
HK (1) HK1045330B (es)
HU (1) HU228068B1 (es)
MX (1) MXPA01009363A (es)
MY (1) MY123371A (es)
NO (1) NO330769B1 (es)
PL (1) PL200384B1 (es)
PT (1) PT1161530E (es)
RU (1) RU2292351C2 (es)
SI (1) SI1161530T1 (es)
SK (1) SK287496B6 (es)
TR (1) TR200102729T2 (es)
WO (1) WO2000056885A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100788219B1 (ko) * 1999-03-18 2007-12-26 메르크 파텐트 게엠베하 혈소판 부착 차단용 단백질
MY128992A (en) 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
AU2002333241B2 (en) * 2001-07-18 2008-09-18 Merck Patent Gmbh Glycoprotein VI fusion proteins
ATE430593T1 (de) 2003-10-28 2009-05-15 Medtronic Inc Verfahren zur herstellung von vernetzten materialien und bioprothetischen vorrichtungen
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
BRPI0515994A (pt) * 2004-10-12 2008-08-19 Univ Michigan State biossìntese de floroglucinol e preparo de 1, 3-dihidróxibenzeno a partir do mesmo
WO2006128152A2 (en) * 2005-05-26 2006-11-30 Thomas Jefferson University Method to treat and prevent posterior capsule opacification
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
JP2009510105A (ja) * 2005-09-28 2009-03-12 バイオバスキュラー インコーポレーティッド 血小板および細胞の接着、細胞移動、および炎症を阻止するための方法および組成物
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
ES2657679T3 (es) 2008-10-15 2018-03-06 Ionis Pharmaceuticals, Inc. Modulación del factor de expresión 11
WO2012003461A2 (en) 2010-07-02 2012-01-05 Draths Corporation Phloroglucinol synthases and methods of making and using the same
WO2012006244A1 (en) 2010-07-06 2012-01-12 Draths Corporation Method for producing phloroglucinol and dihydrophloroglucinol
WO2012006245A1 (en) 2010-07-06 2012-01-12 Draths Corporation Phloroglucinol reductase and methods of making and using the same
EP2606067B1 (en) 2010-08-19 2018-02-21 Zoetis Belgium S.A. Anti-ngf antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
DE202012012998U1 (de) 2011-08-31 2014-06-13 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
AU2013292617A1 (en) 2012-07-19 2015-01-22 Zoetis Llc Bovine influenza C virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
EP3500292A1 (en) 2016-08-17 2019-06-26 Pharmaq AS Sea lice vaccine
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
WO2019177697A2 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
EP3799604A4 (en) 2018-05-09 2022-09-07 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
CN114616325A (zh) 2019-09-11 2022-06-10 硕腾服务有限责任公司 表达禽病原体抗原的重组火鸡疱疹病毒载体和其用途
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
US20210386854A1 (en) 2020-06-15 2021-12-16 Zoetis Services Llc Cell Line for Production of Marek's Disease Virus Vaccine and Methods of Making and Using the Same
AU2021358987A1 (en) 2020-10-07 2023-05-11 Zoetis Services Llc Anti-ngf antibodies and methods of use thereof
TW202221039A (zh) 2020-10-19 2022-06-01 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
CN118076634A (zh) 2021-09-27 2024-05-24 硕腾服务有限责任公司 抗TGFβ1、2、3抗体及其治疗用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705355A (en) * 1984-03-27 1998-01-06 Transgene, S.A. Hirudin, pharmaceutical compositions comprising it and their use
US4898734A (en) 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
IL86857A (en) * 1988-06-24 1994-04-12 Yissum Res Dev Co Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
US5182260A (en) * 1989-01-27 1993-01-26 Biogen, Inc. Dna sequences encoding snake venom inhibitors of platelet activation processes for producing those inhibitors and compositions using them
CA2052486A1 (en) * 1990-10-09 1992-04-10 Thomas M. Connolly Protein for inhibiting collagen-stimulated platelet aggregation
GB9022040D0 (en) * 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
DE4136513A1 (de) * 1991-11-06 1993-05-13 Basf Ag Neues thrombininhibitorisches protein aus raubwanzen
CA2143416C (en) * 1993-07-01 2003-06-10 Jurgen Hemberger Inhibitor of collagen-stimulated platelet aggregation
EP0711158B2 (en) 1993-07-29 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
WO1996008563A1 (en) * 1994-09-12 1996-03-21 Schering Aktiengesellschaft Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
WO1996013585A1 (en) * 1994-10-28 1996-05-09 Clodica S.A. A novel family of protease inhibitors, and other biologic active substances
KR100788219B1 (ko) 1999-03-18 2007-12-26 메르크 파텐트 게엠베하 혈소판 부착 차단용 단백질
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen

Also Published As

Publication number Publication date
CN1185344C (zh) 2005-01-19
ATE295883T1 (de) 2005-06-15
NO20014506L (no) 2001-11-16
DE60020220D1 (de) 2005-06-23
US7090986B2 (en) 2006-08-15
NO330769B1 (no) 2011-07-11
JP2002539788A (ja) 2002-11-26
CA2367457C (en) 2010-09-21
CZ20013341A3 (cs) 2002-01-16
KR20020008131A (ko) 2002-01-29
KR100788219B1 (ko) 2007-12-26
HUP0200353A3 (en) 2003-12-29
AR023099A1 (es) 2002-09-04
PL200384B1 (pl) 2008-12-31
CZ301524B6 (cs) 2010-03-31
ES2240067T3 (es) 2005-10-16
EP1161530A1 (en) 2001-12-12
HK1045330A1 (en) 2002-11-22
HU228068B1 (en) 2012-09-28
EP1161530B1 (en) 2005-05-18
MXPA01009363A (es) 2002-06-04
TR200102729T2 (tr) 2002-04-22
NO20014506D0 (no) 2001-09-17
US6774107B1 (en) 2004-08-10
DK1161530T3 (da) 2005-08-08
SK287496B6 (sk) 2010-12-07
MY123371A (en) 2006-05-31
PL350147A1 (en) 2002-11-04
AU3166200A (en) 2000-10-09
CA2367457A1 (en) 2000-09-28
WO2000056885A1 (en) 2000-09-28
HK1045330B (zh) 2005-09-09
PT1161530E (pt) 2005-09-30
JP4805461B2 (ja) 2011-11-02
SK12902001A3 (sk) 2002-03-05
HUP0200353A2 (hu) 2002-05-29
BR0009074A (pt) 2002-01-02
US20050065084A1 (en) 2005-03-24
AU767172B2 (en) 2003-11-06
RU2292351C2 (ru) 2007-01-27
SI1161530T1 (en) 2005-10-31
CN1344318A (zh) 2002-04-10
US20060094079A1 (en) 2006-05-04
US6962801B2 (en) 2005-11-08
DE60020220T2 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
CO5241328A1 (es) Constructo de adn para la obtencion recombinante de saratina
EP1280540B1 (en) Modified factor viii
Nishida et al. Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of Bothrops jararaca
C. Schröder et al. Stimulation of protein (collagen) synthesis in sponge cells by a cardiac myotrophin‐related molecule from Suberites domuncula
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
HUP9800075A2 (hu) Nukleinsav-konstrukciók proteázokkal aktíválható hatóanyagok expresszálására valamint előállításuk és alkalmazásuk
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
DE69434538D1 (de) Vaskularer endothelialer wachstumsfaktor 2
DK572487D0 (da) Fremgangsmaade til fremstilling af human vaekstfaktor fra endotheliale celler
DE3684892D1 (de) Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens.
DK0808367T3 (da) Vaskulære slimhindeaddressiner samt anvendelse deraf
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
DE68914316T2 (de) Polypeptide aus Vipergift und deren Genexpression.
JPH01250399A (ja) トリグラミン、血小板凝集抑制性ポリペプチド
HUP0002472A2 (hu) Izolált dendritikus sejtmembrán-fehérje gének
EP0382451A3 (en) Viper venom polypeptides and variants
HUP9900979A2 (hu) Endoteliális sejtek proliferációját gátló inhibitor és eljárás alkalmazására
PT1078054E (pt) Mp52/gdf-5 monomérica com actividade morfogenética do osso e agente medicinal contendo a mesma para a prevenção e tratamento de doenças da cartilagem e do osso
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
JP4701355B2 (ja) プロトロンビン活性化タンパク質
US5851983A (en) Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
ECSP003383A (es) Proteina para bloquear la adherencia plaquetaria
US5876971A (en) Thrombin inhibitor from the saliva of protostomia
YU61893A (sh) Modifikovani faktor-4 krvnih pločica
DE69832299D1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed